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ABSTRACT
Background: Successful transplantation of solid organs relies on long-term immunosuppression for the prevention of
graft rejection. Donor-specific tolerance without the need for continuous immunosuppression can be observed after
allogeneic BMT. However, its routine use for tolerance induction has been precluded so far by the high condition-
ing-related toxicity of standard BMT regimens. Our laboratory has recently established a cyclophosphamide (CTX)
plus thymic irradiation (TI)-based nonmyeloablative conditioning protocol for the treatment of hematologic malig-
nancies. We have recently described the successful clinical application of this approach for the induction of donor-
specific tolerance in a patient receiving a living-related kidney transplant, which resulted in graft acceptance without
long-term immunosuppression. The aim of this study was to evaluate the induction and maintenance of host-
versus-graft tolerance following this CTX-plus-TI–based regimen in a mouse model. 
Methods: Induction of mixed hematopoietic chimerism and development of donor-specific tolerance following the
CTX-based nonmyeloablative conditioning regimen (200 mg/kg CTX, in vivo T-cell depletion [anti-CD4 monoclo-
nal antibody (MoAb) GK1.5 and anti-CD8 MoAb 2.43], and 7 Gy TI) was studied in the fully major histocompatibil-
ity complex (MHC)-mismatched B10.A (H2a)→B6 (H2b) strain combination. 
Results: The conditioning regimen allowed allogeneic bone marrow engraftment and persistent (>30 weeks) mixed
lymphohematopoietic chimerism in almost all recipients. TI was essential to allow engraftment and development of
tolerance, which was evident in all lasting chimeras. Compared to animals receiving a similar TBI-based condition-
ing regimen, overall levels of chimerism were significantly lower in the CTX-plus-TI–conditioned animals. How-
ever, donor-specific tolerance in vitro and in vivo was evident in CTX-plus-TI–conditioned chimeras. Tolerance was
associated with the presence of donor-type MHC class II+ cells in the thymus and deletion of donor-reactive cells, as
determined by Mtv-8 and Mtv-9 superantigen-mediated deletion of Vβ11+ and Vβ5/1.2+ T cells.
Conclusion: Engraftment, long-term chimerism, and induction of donor-specific tolerance can be achieved using a
nonmyeloablative CTX-based conditioning regimen in fully MHC-mismatched BMT recipients without the induc-
tion of GVHD.
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INTRODUCTION
Currently, pharmacological long-term immunosuppres-
sion is the only standard clinical treatment modality for the
prevention of graft rejection in patients following solid
organ transplantation. Although this approach is very suc-
cessful and has enabled the widespread application of solid
organ transplantation, there are considerable disadvantages
to the lifelong use of immunosuppressive medication.
Induction of donor-specific tolerance would obviate the
need for nonspecific immunosuppressive therapy while
retaining immunocompetence and is considered the ulti-
mate goal in transplantation medicine. It has long been
recognized that mixed hematopoietic chimerism is accom-
panied by the development of donor-specific tolerance
without the need for long-term immunosuppression [1].
However, in humans, allogeneic bone marrow transplanta-
tion (BMT) in the context of myeloablative conditioning
therapy is hampered by high treatment-related toxicity and
the complication of graft-versus-host disease (GVHD), which
is induced by alloreactive T cells in the graft. One pathogenic
factor contributing to the development of GVHD is thought
to be the inﬂammatory response to the preparative condition-
ing therapy usually needed for engraftment of allogeneic
pluripotent hematopoietic stem cells in humans. Due to this
high conditioning-related toxicity, patients older than
55 years or with organ dysfunction are usually not eligible for
allogeneic BMT. Thus, it is a major goal to develop less toxic
conditioning therapies for allogeneic BMT.
Recently, it has been demonstrated that mixed lympho-
hematopoietic chimerism can be established, even across
major histocompatibility complex (MHC) barriers, by non-
myeloablative conditioning therapies in rodents [2] and large
animals [3-6] and, recently, also in humans [7-9]. A total
body irradiation (TBI)-based nonmyeloablative conditioning
regimen consisting of 3 Gy TBI, in vivo T-cell depletion of
the host, and 7 Gy thymic irradiation (TI) [2] has been estab-
lished. Without inducing prolonged myelosuppression, this
regimen led to multilineage hematopoietic chimerism and
donor-speciﬁc tolerance, with preservation of immunocom-
petence as indicated by third-party alloreactivity in fully allo-
geneic MHC-mismatched murine strain combinations. Fur-
ther decreases in conditioning-related toxicity were achieved
by replacing TI with additional T-cell depletion or blockade
of costimulatory molecules (CD40 or CD28) [10]. T-cell
depletion and TI can both be avoided when 2 costimulatory
blockers are given together [11]. Administration of high
doses of stem cells has been shown to obviate the need for
TBI in the conditioning regimen [12], and a regimen lacking
any host preconditioning has been developed using costimu-
latory blockade and high-dose BMT [13]. These develop-
ments have paved the way to make allogeneic BMT applica-
ble for the treatment of nonmalignant hematopoietic (eg,
hemoglobinopathies, severe aplastic anemia) disorders and
autoimmune diseases or for the induction of tolerance in the
context of solid-organ transplantation.
In a modification of the TBI-based nonmyeloablative
regimen described above [2] that was tailored for the treat-
ment of hematologic malignancies, we recently showed that
cyclophosphamide (CTX) could be used in place of low-dose
TBI to achieve mixed chimerism in mice [14]. This approach
was extended to a clinical trial involving patients with refrac-
tory hematologic malignancies [7,8]. The potential of this
protocol to also induce allograft tolerance is underscored by
a recent clinical observation, in which a patient with end-
stage renal disease due to multiple myeloma received this
nonmyeloablative treatment protocol with a simultaneous
bone marrow and kidney transplant from a living HLA-
identical sibling. Despite discontinuing the immunosuppres-
sive therapy (cyclosporin A) by day 73, the patient accepted
the kidney graft, demonstrating the successful induction of
tolerance [15]. The aim of the current study was to assess the
potential of this protocol to induce tolerance across full
MHC barriers as well as the mechanisms underlying the
induction of tolerance following this CTX-plus-TI–based
conditioning regimen in the murine model.
MATERIALS AND METHODS
Animals
B10.A (H-2a: Kk, Ak, Ek, Dd, Ld) female donor mice pur-
chased from Frederick Cancer Research Facility, National
Cancer Institute (NCI-Frederick) (Frederick, MD), were used
at 8 to 12 weeks of age. Female C57BL/6 (B6: H-2b, I-E–)
recipient mice were purchased from NCI-Frederick, and
used after 8 weeks of age. A.SW (H-2s) and B10.RIII (H2r)
mice were used as third-party donors for cell-mediated lym-
pholysis (CML), mixed lymphocyte reaction (MLR) assays,
and skin-grafting experiments. All mice were housed in
autoclaved microisolator environments, and all manipula-
tions were performed in a laminar ﬂow hood.
Preparation of Chimeras
Two preparative regimens were used in this study. Con-
trol chimeras were prepared using our “standard” TBI-
based nonmyeloablative regimen as previously described [2]
and are referred to as TBI chimeras. Briefly, recipient B6
mice were treated on day –5 with depleting doses of anti-
CD8 monoclonal antibody (MoAb) 2.43 (1.4 mg) and anti-
CD4 MoAb GK1.5 (2.0 mg) intraperitoneally (IP) in sterile
phosphate-buffered saline. On day 0, recipient mice were
treated with 7 Gy TI from a 60Co source and 3 Gy TBI
from a 137Cs source.
The second nonmyeloablative preparative regimen, in
which CTX was substituted for TBI, has recently been
developed in our laboratory [14]: instead of TBI on day 0,
mice received 200 mg/kg CTX IP on day –1. To test the rel-
evance of TI, we also prepared chimeras using the CTX
regimen without TI. Bone marrow was harvested and single
cell suspensions prepared as described [16]. Approximately 4
hours after the completion of TI, each recipient was injected
intravenously through the lateral tail vein with 20 × 106
donor bone marrow cells.
Phenotyping of Chimeras
Chimerism in white blood cells (WBCs), spleen, bone
marrow, and thymus was assessed by 2-color or 3-color
flow cytometry (FCM) using a FACScan cytometer (Bec-
ton Dickinson, Mountain View, CA). Thymi and spleens
were harvested and gently teased in bone marrow medium
(Medium 199 [Mediatech, Herndon, VA], containing
2 µg/mL DNAse, 0.01 mol/L HEPES buffer [Biowhit-
taker, Walkersville, MD], and 4 µg/mL gentamycin) or in
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ammonium chloride-potassium–lysing buffer (BioWhit-
taker), respectively. Single-cell suspensions were filtered
through nylon mesh. Bone marrow was recovered from
femora and tibiae by flushing the bone marrow cavity.
Peripheral blood was collected into heparinized Eppendorf
tubes and subjected to deionized water lysis.
Two-color staining was performed using MoAbs directly
labeled with ﬂuorescein isothiocyanate (FITC), phycoerythrin
(PE), or biotin (Bio), followed by subsequent development
of Bio-labeled MoAbs with PE-conjugated streptavidin. To
reduce nonspecific binding of MoAbs, 10 µL of 2.4G2
(anti–Fcγ-RII receptor, CDw32) hybridoma supernatant
[17] was added to all tubes. The following antibodies were
used for chimerism analyses: anti–CD4-FITC, anti–CD8β-
FITC, anti–B220-FITC (all purchased from Pharmingen,
San Diego, CA), anti–Mac-1-FITC (CalTag, San Francisco,
CA), and 34-2-12-Bio (anti–H2-Dd). Nonreactive control
MoAb HOPC-FITC or HOPC-Bio (immunoglobulin [Ig]
G2a prepared in our laboratory) and rat IgG2b-PE (Pharmin-
gen) were used as negative controls. The percentage of
donor cells within each leukocyte population was deter-
mined as previously described [18]. Exclusion of dead cells
was performed by propidium iodide (PI) staining and live
gating on PI-negative cells. Ten thousand events were col-
lected and analyzed. The different peripheral blood leuko-
cyte populations were distinguished by their forward scatter
(FSC) and side scatter (SSC) properties: FSC low and SSC
low (lymphocytes), SSC high (granulocytes), and FSC high
and SSC low (monocytes).
Flow Cytometric Analysis of T-Cell Receptor V
Subfamilies
Triple-color staining was performed for the analysis of
thymic cell populations using FITC-conjugated (anti-
Vβ5.1/2, anti-Vβ11, anti-Vβ8.1/2, HOPC), PE-labeled
(anti-CD4, rat IgG2a), and Bio-labeled antibodies (HOPC,
34-2-12, anti-CD8β). Staining by Bio was developed using
streptavidin-conjugated CyChrome (Pharmingen). Deletion
of Vβ5.1/2+ and Vβ11+ thymocytes was assessed by live gat-
ing on CD4+CD8– mature thymocytes. Five thousand gated
cells were acquired. Nonspeciﬁc binding was determined by
HOPC-FITC staining and was subtracted from the per-
centage of cells staining with each FITC-labeled Vβ MoAb.
Expression of Vβ8.1/8.2+, which are not deleted in I-E+ ani-
mals, served as a control. Deletion of splenic Vβ5.1/2+ and
Vβ11+ T cells was determined by 2-color staining with
FITC-conjugated anti-Vβ5.1/2, anti-Vβ11, and anti-Vβ8
MoAbs versus CD4-PE and live gating on CD4-PE positive
cells. Ten thousand gated events were analyzed. Nonspeciﬁc
staining with HOPC-FITC was subtracted as described
above.
Immunohistochemical Staining
Immunohistochemical analysis of thymic chimerism was
performed as previously described [11,12,19]. Brieﬂy, sections
were prepared from frozen thymus tissue by using a Tissue
Tek cryostat. After ﬁxation and blocking, the specimens were
incubated with MoAb, 25-9-17 (anti–I-Ab, IgG2a), ISCR-3
(anti-IE, IgG2b), HOPC (IgG2a control), and 74.11.10
(IgG2b control). After washing, slides were incubated with a
biotinylated secondary MoAb followed by development with
streptavidin-conjugated horseradish peroxidase (Vectastain;
Vector Labs, Burlingame, CA) and AEC (20 mg of 3-amino-
9-ethylcarbazole, dissolved in 2.5 mL of dimethyl formamide
and 47.5 ml of 0.1 mol/L acetate buffer) for 2 minutes. The
specimens were then immersed in 2% paraformaldehyde in
0.05 mol/L sodium phosphate buffer for 10 minutes. Coun-
terstaining was performed using hematoxylin.
CML Assay
Spleen cells from normal control animals and BMT recip-
ients were suspended in CML medium as previously described
[12,13]. Responder and stimulator cells were diluted to a con-
centration of 8 × 106 cells/mL. Stimulator cells were irradiated
with 3000 rad using a 137Cs source. A total of 8 × 105 stimula-
tor cells were cocultured with 8 × 105 responder cells in
96-well U-bottom plates. Cultures were set up in 2 rows of
3 replicates each. After 5 days of culture at 37°C, 2-fold serial
dilutions were prepared from the second row of triplicates so
that cytolytic activity could be determined at 5 different
responder-to-target ratios. A total of 8 × 103 51Cr-labeled con-
canavalin A–stimulated lymphoblasts were added to each well
and incubated for 4 hours at 37°C. Plates were harvested by
using a Titertek supernatant collection system (Skatron, Ster-
ling, VA), and 51Cr release was determined with an automated
gamma counter (Canberra-Packard, Meridien, CT). Percent
speciﬁc lysis (PSL) was calculated using the formula: PSL =
100% × (experimental release – spontaneous release/maxi-
mum release – spontaneous release).
Mixed Lymphocyte Reaction
Spleen cells from normal control animals and BMT
recipients were cultured in triplicate wells in serum-free
MLR medium as previously described [12,13]. Stimulator
cells were irradiated with 3000 rad using a 137Cs source.
Four hundred thousand stimulator cells were cocultured
with 4 × 105 responder cells in 96-well ﬂat-bottom plates for
3 to 4 days at 37°C before they were pulsed with 1 µCi of
3H-thymidine per well for the last 16 to 18 hours of culture.
Thereafter, cells were harvested on glass ﬁlter mats using a
Tomtec harvesting device (Hamden, CT). 3H-thymidine
incorporation was measured using a betaplate beta counter.
Stimulation index was determined by comparing antidonor
response and anti–third-party response with anti-host
response according to the formula: cpm antidonor (or
anti–third party)/cpm antihost. The counts per minute
obtained for antihost were generally similar to or lower than
those obtained in the absence of stimulator cells.
Skin Grafting
Skin grafting with donor and third-party full-thickness
tail skin was performed as previously described [19]. On day
7, bandages were removed and skin grafts were evaluated
daily for signs of rejection or infection. Grafts were consid-
ered rejected when less than 10% of the graft bed contained
viable grafted skin.
Statistical Analysis
Group means were compared using Student t test with
Microsoft Excel software. A P value of less than .05 was con-
sidered to be signiﬁcant. All experiments reported here were
performed at least 3 times.
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RESULTS
TI Is Necessary for the Development of Durable
Mixed Lymphohematopoietic Chimerism
We have previously shown that the CTX-plus-TI–based
nonmyeloablative conditioning regimen described in “Mate-
rials and Methods” allows engraftment and establishment of
mixed hematopoietic chimerism when BMT is performed in
fully MHC-mismatched strain combinations [14]. In the
B10.A-to-B6 combination used here, lasting chimerism
develops in about 90% of animals [14]. To evaluate the
requirement for TI in this regimen and compare chimerism
achieved with TBI versus CTX, 3 experimental groups were
prepared: (1) the CTX-based regimen, including TI; (2) the
above CTX-based regimen, without TI; and (3) our stan-
dard TBI regimen. Figure 1 shows the engraftment kinetics
and the time course of chimerism in the peripheral blood
leukocytes of the 3 groups. Animals that did not receive TI
failed to engraft or showed only transient minimal levels of
donor-type cells in the peripheral blood. Furthermore, ani-
mals receiving TBI conditioning had significantly higher
levels of chimerism in all lineages compared to the group
treated with CTX plus TI. Differences in levels of chimerism
were statistically signiﬁcant at each time point. Two animals
from the TBI group with relatively low levels of chimerism
died 15 weeks after BMT during the process of skin graft-
ing, thus explaining the increase in the mean chimerism
level in this group at 15 weeks.
Comparison of Chimerism in Hematopoietic Tissues
of CTX Versus TBI Chimeras
We compared levels of chimerism in the lymphohe-
matopoietic system in CTX- and TBI-conditioned mice.
Mice were killed between days 219 and 232 post-BMT and
studied for organ chimerism in the spleen, bone marrow,
and thymus. Table 1 depicts chimerism results in marrow
and spleen. Data on thymic chimerism are presented in
Table 2. Mixed chimerism was observed in all tissues of
7/8 B6 recipients that had been treated with the full CTX
regimen. One animal developed a skin infection after skin
grafting and subsequently lost chimerism; it is presented
separately in Tables 1 and 2. In mice receiving this condi-
tioning regimen, donor-derived cells were found predomi-
nantly in the lymphoid lineages and, to a lesser extent,
among the myeloid lineages. In contrast to these results, the
standard TBI regimen led to a signiﬁcantly higher (P < .05)
level of donor cell engraftment in the lymphoid and myeloid
lineages within bone marrow and spleen (Table 1). Although
statistical signiﬁcance was not achieved (P = .08), chimerism
appeared to be higher in the Mac-1+ population, and signiﬁ-
cantly higher chimerism was observed among B220+ cells in
the bone marrow of the TBI group. Chimerism was also
detected among thymocytes in CTX chimeras (Table 2).
However, a significantly higher level of donor thymocyte
chimerism was detectable in the thymus of TBI animals
(Table 2). Animals that received the CTX conditioning regi-
men without TI failed to show any detectable donor cells in
any of the tissues studied.
Donor-Specific Tolerance in CTX Chimeras
Next, we studied the induction of donor-speciﬁc toler-
ance and its mechanism in B10.A→B6 chimeras prepared
with the CTX-based regimen. We analyzed tolerance in
vitro using CML and MLR assays, which were performed
when animals were killed 31 to 33 weeks post-BMT. As is
Figure 1. TI is required for sustained WBC chimerism in mice receiving BMT with the CTX-based nonmyeloablative conditioning regimen.
Time course of WBC chimerism in mice treated with either the standard TBI-based conditioning regimen (TBI, n = 5), the CTX regimen without
TI (CTX – TI, n = 8), or the full CTX regimen (CTX + TI, n = 8). Within the TBI group, 2 animals with low levels of donor chimerism died dur-
ing the process of skin grafting, leading to an increase in the mean chimerism level in this group after week 15. The mean and the standard error of
the mean are presented.
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shown in Table 3, B10.A→B6 recipient mice treated
with the CTX regimen revealed unresponsiveness to the
B10.A donor in CML and MLR assays. For most animals,
anti–third-party reactivity was evident in CML assays,
demonstrating donor-speciﬁc CML tolerance. Nevertheless,
anti–third-party CML responses in some experiments
tended to be lower than those in untreated B6 control mice,
which could be explained by the fact that the control ani-
mals were not age matched and thus were considerably
younger than the experimental animals. Similar results were
obtained for TBI chimeras. With both types of chimeras,
anti–third-party MLR responses were frequently not mea-
surable, probably reﬂecting the fact that A.SW is a particu-
larly weak stimulator of MLR responses in mice that are
tolerant of this donor and recipient strain, regardless of the
regimen used to achieve tolerance (J. Kurtz, M.S., unpub-
lished data, 1998). Nevertheless, the nontolerant (no TI)
BMT recipients mounted signiﬁcant responses to the donor
(but also not to third party), consistent with the interpreta-
tion that TBI and CTX chimeras (treated with TI) were tol-
erant to their donors in the MLR assay.
One representative CML assay showing donor-speciﬁc
tolerance in CTX-treated animals is depicted in Figure 2. As
expected from the results presented above, animals receiving
CTX without TI were not tolerant toward the marrow
donor (Table 3 and Figure 2). The TBI-treated animal
(#137/8) was specifically unresponsive toward donor and
host cells, as previously described [2]. Third-party reactivity
against A.SW (H2S) stimulators was evident.
CTX Conditioning Therapy and BMT Lead to
Acceptance of Fully MHC-Mismatched Donor 
Skin Grafts
Acceptance of donor-speciﬁc skin grafts is considered to
be the most stringent test of tolerance. To measure donor-
specific tolerance in vivo in chimeras prepared with the
CTX regimen, skin transplantation was performed 16 weeks
post-BMT. Animals received skin grafts from the bone
Table 1. Lymphohematopoietic Chimerism in Spleen and Bone Marrow
Normal B6 Normal B10.A B10.A→B6 B10.A→B6
Controls,* Controls, Chimeras TBI,† Chimeras CTX,†
Mean % H2Dd+ Cells Mean % H2Dd+ Cells Mean % H2Dd+ Cells Mean % H2Dd+ Cells TBI Versus
± SD (n = 3) ± SD (n = 3) ± SD (n = 3) ± SD (n = 7)‡ CTX, P
Bone Marrow
B220 0.06 ± 0.06 99.84 ± 0.27 57.34 ± 16.40 4.17 ± 2.77 <.05
Mac-1 0.13 ± 0.20 97.77 ± 1.57 43.32 ± 22.06 2.3 ± 1.45 .08
Spleen
CD4 0.13 ± .12 100 ± 0 50.08 ± 2.63 9.14 ± 5.76 <.05
CD8 0 ± 0 100 ± 0 55.97 ± 16.21 7.61 ± 6.88 <.05
B220 0.51 ± 0.08 100 ± 0 53.94 ± 6.34 5.72 ± 2.77 <.05
*Untreated B6 and B10.A mice were used as controls.
†Animals from experimental groups (TBI and CTX) were killed 219, 226, and 232 days after BMT.
‡One animal (#129/30) was excluded due to development of skin infection after skin grafting and loss of chimerism.
Table 2. Thymic Deletion and Chimerism
Deletion of CD4+CD8– TCR V Subfamilies* Thymic Chimerism
%V8+ Cells, %V11+ Cells, %V5+ Cells, %Donor Cells, Donor Cells
Mean ± SD Mean ± SD Mean ± SD MHC I+†, Mean ± SD MHC II+‡
Normal B6 (n = 3)§ 18.92 ± 0.48 4.74 ± 0.35 3.67 ± 0.71 0.27 ± 0.39 –
Normal B10.A (n = 3) 17.72 ± 0.73 0.24 ± 0.13 0.19 ± 0.03 60.33 ± 5.55 +
TBI (n = 3) 21.90 ± 2.16 0.28 ± 0.15 0.31 ± 0.19 18.39 ± 17.53 3/3
CTX without TI (n = 3) 18.67 ± 0.20 4.80 ± 0.15 3.81 ± 0.62 0.14 ± 0.13 –
CTX
Stable chimeras (n = 7) 21.73 ± 3.06 0.95 ± 0.72 0.81 ± 0.63 0.91 ± 0.90 3/6¶
Unstable chimera# 20.63 4.42 2.28 0.03 –
*Deletion studies: CTX plus TI versus TBI: Vβ5.1/2, NS; Vβ11, P < .05; CTX plus TI versus CTX no TI: Vβ5.1/2, P < .01; Vβ11, P < .0005;
CTX no TI versus TBI: Vβ5.1/2, P < .01; Vβ11, P < .00001.
†MHC class I H2Dd+ thymocytes were detected by FCM.
‡MHC class II+ cells with dendritic cell morphology were detected by immunohistochemical staining of thymic tissue with a MoAb speciﬁc for
donor MHC class II.
§Normal untreated B6 mice were used as controls.
One B6 animal was excluded due to high nonspeciﬁc staining.
¶Only 6 samples were available for histological analysis.
#Animal #129/30 developed a skin graft infection, lost its chimerism, and rejected its skin graft. Therefore, its results are presented separately.
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marrow donor strain (B10.A) and from third-party donors
(B10.RIII). In addition, animals that had been conditioned
with the CTX regimen without TI received similar grafts.
The survival curves for the skin grafts are presented in Fig-
ure 3. Whereas third-party B10.RIII grafts were rapidly
rejected by day 11 in all groups, B10.A donor skin grafts
were accepted for more than 100 days (ie, until the end of
the observation period) in all CTX and TBI chimeras
tested. The 1 animal prepared with the CTX/TI regimen
that rejected its donor graft on day 29 had lost its chimerism.
In contrast, animals that had received the CTX regimen
without TI rejected their B10.A grafts by day 13.
Thymic Chimerism and Deletion of Donor-Reactive
Cells Are Associated With the Presence of Donor-Type
MHC Class II+ Cells in the Thymus
Donor-specific tolerance following BMT has been
shown to be associated with intrathymic clonal deletion of
donor-reactive cells [20,21]. To determine the mechanism
underlying the maintenance of tolerance following our
CTX regimen, we analyzed chimerism and deletion of
donor-reactive thymocytes. Using FCM, donor-type cells
(H2-Dd) were detectable among the thymocytes of most
CTX chimeras killed at 31 to 33 weeks post-BMT (14 of
17 animals; Table 2 and data not shown). However, the level
of thymocyte chimerism was much lower in these mice than
in chimeras prepared with the TBI-based standard regimen
(Table 2). A similar observation was made with regard to
donor-type MHC II+ cells in the thymus, as demonstrated
by immunohistochemical staining of thymic tissue. Whereas
donor-type MHC class II+ cells were abundant in the
medulla of the thymi of animals treated with the TBI regi-
men (3/3), rare MHC class II+ cells of donor origin were
detectable in only 3/6 CTX chimeras. Figure 4 depicts
1 representative thymic section of a CTX chimera stained
for donor and host MHC class II+ cells. In contrast, animals
that had received the CTX regimen without TI were com-
pletely devoid of thymic chimerism and of donor MHC
class II+ cells in the thymus (0/3) (Table 2).
To determine the fate of host-derived donor-reactive
cells, we followed host-derived superantigen-reactive
Vβ5.1/2+ and Vβ11+ T-cell receptor (TCR) subpopulations
in mixed chimeras by FCM. Vβ5.1/2 and Vβ11 TCR sub-
units bind to superantigens derived from mammary tumor
virus 8 and 9 endogenous retroviruses encoded in the
B6/B10 background genome, which are presented by MHC
class II I-E antigens. Thus, Vβ5.1/2- and Vβ11-expressing
thymocytes are clonally deleted in the thymus of I-E+
(B10.A) animals, but not in I-E– (B6) mice. We evaluated
Vβ5.1./2+ and Vβ11+ T-cell populations in spleens and
thymi of mixed chimeras.
The majority of CTX chimeras and all TBI chimeras
showed complete or near-complete deletion of donor-reactive
T cells, as determined by deletion of Vβ5/1.2+ and Vβ11+
Table 3. Correlation of Splenic Deletion and Donor-Speciﬁc Tolerance*
MLR, Stimulation Index CML, Maximum PSL Deletion of Splenic CD4+ V Subfamilies
-Donor -Third Party† -Donor -Third Party V8 V11 V5.1/2
B6 (n = 3) 11.1 ± 6 5.1 ± 1.9 44.9 ± 6.2 52.9 ± 10.4 17.4 ± 1.3 4.8 ± 0.3 2.5 ± 0.0
B10.A (n = 3) 1.0 ± 0 3.4 ± 1.0 7.3 ± 1 ND 17.4 ± 1.0 0.2 ± 0.1 0.1 ± 0.1
TBI (n = 3) 1.0 ± 0.1 1.9 ± 1 5.4‡ 12.2 21.4 ± 1.5 0.4 ± 0.4 0.4 ± 0.5
CTX without TI (n = 3) 2.4 ± 0.8 1.6 ± 0.2 37.6 ± 12.5 26.4 ± 24.8 16.8 ± 1.9 3.8 ± 0.35 4.2 ± 3.5
CTX plus TI
Stable chimeras (n = 7) 0.9 ± 0.2 1.4 ± 0.3 7.8 ± 3 19.2 ± 3.8 20.7 ± 1.0 0.6 ± 0.4 0.3 ± 0.3
Unstable chimera (#129/30) 1.7 2.7 NE NE 17.41 3.83 1.5
*t test: TBI vs. CTX Vβ8 Vβ5.1/2, Vβ11, NS; TBI vs. CTX no TI, Vβ11 P < .05; CTX plus TI vs. CTX no TI Vβ5.1/2, Vβ11 P < .05. ND
indicates not determined; NE, not evaluable.
†A.SW were used as third-party stimulators.
‡Only 1 animal was evaluated.
Figure 2. Tolerance to donor in CML assays. Spleen cells from representative animals conditioned with the complete cytoxan regimen CTX + TI
(animals 121/2, 123/4, 125/6), CTX without TI (CTX-TI), and the TBI regimen (137/8) were studied with respect to antihost (B6), antidonor
(B10.A), and anti–third-party cytotoxic responses. Normal B6, B10A, and A.SW splenocytes served as controls. All experimental animals were toler-
ant of host (anti-B6). Whereas all CTX + TI chimeras were tolerant of donor (B10.A) and demonstrated anti–third-party reactivity (anti-A.SW), the
animal conditioned without TI (115/6, CTX-TI) showed a vigorous antidonor response.
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mature CD4+CD8– cells in the thymus (Table 2) and of
CD4+CD8– cells in the spleen (Table 3). Because donor
chimerism levels were generally low in CTX chimeras, the
majority of CD4+ cells analyzed for the presence of Vβ5.1/2+
or Vβ11+ subpopulations were of host origin, thus reﬂecting
the deletion of donor-reactive host CD4+ cells. Furthermore,
in the thymus, deletion of superantigen-reactive Vβ5.1/2+ or
Vβ11+ subpopulations appeared to be less complete in CTX
versus TBI chimeras, with statistical significance achieved
only for Vβ11+ (P < .05). However, there was no statistically
signiﬁcant difference with regard to deletion of superantigen-
reactive cells between CTX and TBI chimeras in the spleen.
One animal (#129/30) had completely lost chimerism at the
time of death, showed nontolerance in the MLR assay, and
did not show deletion of these Vβ subpopulations (Tables 2
and 3). In all instances, donor-speciﬁc hyporesponsiveness in
MLR was accompanied by complete or partial clonal deletion
in the spleen and thymus of donor cells as determined by
analysis of Vβ5.1/2+ and Vβ11+ TCR-bearing CD4+ T cells.
Animals that did not receive TI did not show deletion of
superantigen-reactive cells and revealed signiﬁcant antidonor
MLR and CML responses (Tables 2 and 3, Figure 3).
Figure 3. Donor-speciﬁc skin graft tolerance in CTX chimeras. Animals that had received the CTX-based regimen, with or without TI, or the
standard TBI regimen were skin grafted as described in “Materials and Methods.” All CTX- (n = 8) and TBI-treated animals (n = 3) rejected their
third-party grafts (B10.RIII) by day 11, whereas donor-type (B10.A) skin grafts were accepted until the end of the observation period. Animals that
received the CTX treatment without TI (n = 3) rejected their third-party grafts by day 11 and rejected donor grafts by day 13.
Figure 4. Immunohistochemistry of thymic tissues. Immunohistochemical staining of thymic sections of a CTX chimera killed 31 weeks post-BMT
is shown. Donor and host MHC class II+ cells are detectable in the thymus of CTX chimeras. Similar results were obtained in 3 of 6 chimeras pre-
pared with this regimen. 
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DISCUSSION
The widespread application of allogeneic BMT for toler-
ance induction has been precluded thus far by 2 major limi-
tations: first, the toxicity of the conditioning therapy
required for engraftment of donor-derived hematopoietic
stem cells; second, the development of GVHD. Accumulat-
ing data over the last decade have demonstrated that mye-
loablative conditioning is not necessary to induce mixed
hematologic chimerism [2,12,14]. Recently, we were able to
translate these findings into clinical application using a
CTX-based nonmyeloablative conditioning regimen [15].
The current study was undertaken to investigate the toler-
ance induction and maintenance across full MHC barriers in
murine mixed chimeras receiving BMT with the CTX con-
ditioning regimen and to compare it to that achieved with our
standard nonmyeloablative regimen, which is not designed
for the treatment of hematological malignancies. Our data
conﬁrm that the CTX regimen is able to induce long-term
hematopoietic chimerism in fully MHC-mismatched mouse
strain combinations without the induction of GVHD.
Chimerism was most pronounced in the B-cell lineage.
Myeloid chimerism was also observable, but to a lesser extent
compared to chimeras prepared with the TBI regimen. CTX
is predominantly immunosuppressive and has only limited
stem cell toxicity [22], consistent with results from several
groups in which CTX is given on day 2 post-BMT to
deplete alloantigen-activated T cells, and donor marrow
engraftment is still achieved [23,24]. In contrast, low-grade
TBI, although not myelotoxic, is highly stem cell toxic and
leads to a high rate of stem cell engraftment [25].
TI is a crucial component of our CTX-based condi-
tioning therapy, as animals that did not receive TI failed to
engraft or develop donor-specific tolerance. These results
conﬁrm previous data from our laboratory showing that the
administration of T cell–depleting MoAb as used in this
protocol is not sufﬁcient to deplete donor-reactive thymo-
cytes in the standard TBI protocol [26]. However, TI could
be eliminated in the standard protocol by administration of
additional T cell–depleting MoAb [27,28] or using costim-
ulatory blockade with anti-CD40 ligand or cytotoxic
T lymphocyte–associated-4 antigen (CTLA4)-Ig [10].
Because the CTX regimen was primarily designed for the
treatment of malignancies, prolonged in vivo T-cell deple-
tion or suppression is not desirable, because it might miti-
gate graft-versus-tumor effects.
Chimeras prepared with the CTX regimen showed
donor-specific tolerance in vitro and in vivo as assessed
by CML/MLR assays and skin grafting. We evaluated
superantigen-reactive Vβ5.1/2 and Vβ11 T cells as surro-
gate markers for the deletion of donor-reactive cells. Indeed,
we were able to observe intrathymic clonal deletion of these
T-cell subsets in mixed chimeras prepared with the CTX
regimen. Deletion of thymic and splenic donor-reactive
CD4+ cells was evident in stable chimeras that showed toler-
ance to the donor in vitro and in vivo. Using 2C TCR trans-
genic mice as recipients, which carry a transgenic TCR spe-
ciﬁc for a donor MHC class I antigen Ld, we have recently
conﬁrmed that clonal deletion of such donor-reactive cells
occurs in chimeras prepared using the TBI regimen, and
these results concurred with results obtained by assessing
the deletion of superantigen-reactive cells [19].
Induction and maintenance of tolerance following the
TBI regimen has been shown to be associated with the
presence of donor MHC II+ cells in the thymus [21]. This
association appears to be the only significant mechanism
maintaining tolerance in such animals, as administration of
anti-donor MoAb to euthymic mice resulted in loss of
chimerism, deletion, and tolerance [29]. In contrast, when
mice were thymectomized prior to elimination of donor cell
chimerism, tolerance to donor skin grafts persisted despite
the loss of peripheral chimerism. These results indicated
that donor chimerism is required only in the thymus to
maintain (deletional) tolerance. In the absence of a thymus,
tolerance was maintained in the absence of donor antigen in
the periphery, reﬂecting the fact that the T-cell repertoire
had been fully deleted of donor-reactive cells. Anergy and
suppression of donor-reactive cells did not play a role, as
these phenomena depend on the continued presence of
donor antigen. Further evidence against a role for suppres-
sion was the facility with which administration of nontoler-
ant host-type T cells resulted in rapid rejection of donor
grafts and chimerism [29].
Chimerism and the number of donor MHC II+ cells
were signiﬁcantly lower in the thymi of CTX chimeras than
in those of TBI recipients. This observation might also
reﬂect a lower level of stem cell engraftment achieved with
CTX compared to TBI (Table 1), resulting in a reduced
number of donor bone marrow–derived antigen-presenting
cells migrating to the recipient thymus. Nevertheless, dele-
tion of donor-reactive thymocytes was quite extensive,
although not as complete as that observed in TBI chimeras.
In addition, some animals showed partial thymic and splenic
deletion of donor-reactive CD4+ cells but did not have donor
MHC II+ cells detectable in the thymus by immunohisto-
chemistry at the time of death. This ﬁnding suggests that the
number of MHC II+ cells in the thymus of these mice might
be very low and close to the limit of detection and that dele-
tion might still be taking place even with very low numbers
of donor-derived antigen-presenting cells in the thymus.
Another possible explanation for these findings could
be that thymic chimerism disappears over time and that
mechanisms other than deletion play a significant role in
maintaining tolerance in the CTX chimeras. Indeed, dele-
tion of donor-reactive T cells is incomplete in these ani-
mals, and we were able to detect donor MHC class II+ cells
in only half of the CTX-plus-TI–conditioned chimeras
with stable chimerism and donor-specific tolerance. A role
for suppression has been suggested in the long-term main-
tenance of tolerance in rat-mouse chimeras prepared with
a nonmyeloablative regimen, which maintain donor-specific
tolerance beyond the time when chimerism is no longer
detectable [30]. Suppressive mechanisms might lead to a
requirement for an intact thymus in the maintenance of
tolerance in these chimeras, in contrast to results in TBI
chimeras [29]. The induction of tolerance to MHC class
I–disparate, MHC II–matched kidney grafts using a short
course of cyclosporin A was critically dependent on the
presence of a thymus in a miniature swine model not
involving T-cell depletion or BMT [31,32], demonstrating
that the thymus can play a role in maintaining peripheral
tolerance. The role of the thymus in maintaining tolerance
was not addressed in the present study.
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In summary, data presented here show that the CTX
regimen leads to induction of stable mixed hematopoietic
chimerism with the concomitant induction of donor-speciﬁc
tolerance, as indicated by the permanent acceptance of donor
skin grafts and CML results, and that this tolerance develops
in large part via a central deletion mechanism.
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